PRN: Global Metabolic Partnering Deals and Agreements Analysis 2010-2017 - Research and Markets

03/mar/2017 01:30:24 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Metabolic Partnering Deals and Agreements Analysis 2010-2017 - Research and Markets


DUBLIN, Mar. 2, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Metabolic Partnering 2010-2017: Deal trends, players and financials" report to their offering.

Global Metabolic Partnering 2010 to 2017 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

Global Metabolic Partnering 2010 to 2017 includes:

  • Trends in Metabolic dealmaking in the biopharma industry since 2010
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 3500 Metabolic deal records
  • The leading Metabolic deals by value since 2010
  • Most active Metabolic dealmakers since 2010

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in Metabolic dealmaking

3. Financial deal terms for Metabolic partnering

4. Leading Metabolic deals and dealmakers

5. Metabolic contract document directory

6. Metabolic dealmaking by therapeutic target

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl